tonic-clonic seizure News
-
Brain Sentinel Announces Launch of SeizureLink, its sEMG-Based Seizure Alerting System, Available Without a Prescription
Brain Sentinel Consumer Systems, LLC (herein “Brain Sentinel”) announces the global launch of its new SeizureLink™ Alerting System at the Epilepsy Foundation’s “2018 Epilepsy Pipeline Conference”, currently being held in San Francisco, CA. Pre-ordering for the U.S. will begin in March 2018, with shipments planned to begin by mid-summer via SeizureLink.com. ...
-
Brain Sentinel’s SPEAC® System Demonstrates Equivalence in Sensitivity to Detect Generalized Tonic Clonic Seizures to Video EEG
Brain Sentinel’s SPEAC® System demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). In a new study published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) biomarker demonstrated ...
-
Brain Sentinel’s SPEAC® System Named `Best of What’s New` for 2017 by Popular Science Magazine
Popular Science magazine has named the SPEAC® System "Best of What’s New in 2017" in the Health category. The SPEAC® System is the first FDA-cleared, non-EEG, physiological, signal-based system for seizure monitoring. "We are excited and thrilled by this award from Popular Science," said Mike Girouard, President, CEO and co-founder of Brain Sentinel, Inc. Girouard ...
-
Publications by our customers - current trends
We took a look at the number of publications created using BESA software. And we need to conclude: the trend is positive! Each year, more publications get generated where BESA software is used. In particular, over the last couple of years BESA Statistics and BESA Connectivity featured much more frequently than before, reflecting the trend to analyze brain connectivity, and to present ...
By BESA GmbH
-
Brain Sentinel, Inc. Announces New FDA 510(k) Clearance for its First-in-Class SPEAC® System Helping Physicians Characterize Seizure Events
Brain Sentinel, Inc., manufacturer of the first FDA-cleared portable seizure monitoring and alerting technology utilizing surface electromyography (sEMG), announced that its SPEAC® System has received a new 510(k) clearance of expanded indications from the U.S. Food and Drug Administration (FDA). Brain Sentinel, Inc., manufacturer of the first FDA-cleared portable seizure monitoring ...
-
Brain Sentinel, Inc. Announces the Purchase of IctalCare A/S Assets
Brain Sentinel, Inc., a Texas company, has purchased the assets of IctalCare A/S, a Danish company. These assets include intellectual property, and a non-prescription, wearable device designed to monitor for seizure activity. "We are excited to add to our product line a small, wearable surface electromyography (sEMG) monitor that consumers may order and use without a prescription," said Mike ...
-
Worldwide first absence seizure tracker becomes available to Australian families
More than 250,000 people are living with epilepsy in Australia, of which 1 in 7 are having difficult-to-notice absence seizures. Such seizures are different from tonic-clonic (convulsive) seizures, and are typically shorter in length, with a brief loss of consciousness. Even though this type of seizure usually does not lead to physical injury, it has a major impact on the wellbeing of the person ...
By Epihunter NV
-
Brain Sentinel Diagnostic Services LLC Receives Innovative Technology Contract from Vizient for the SPEAC System
Brain Sentinel Diagnostic Services LLC announced that it has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country. Brain Sentinel Diagnostic Services is an independent diagnostic testing facility that provides the SPEAC® System. The new multi-year contract began in April 2019 and is based on a ...
-
Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation partner on vaccination program with GARDASIL(R) for girls and young women of Bhutan
The Royal Government of Bhutan, Merck (which is known as MSD outside the United States and Canada) and the Australian Cervical Cancer Foundation (ACCF) today launched a national vaccination program with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls and young women in Bhutan. In an effort to reduce the burden of cervical cancer, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you